Literature DB >> 15253716

Dopamine D2-like receptor agonist bromocriptine protects against ischemia/reperfusion injury in rat kidney.

Vihang Narkar1, Oksana Kunduzova, Tahir Hussain, Claudie Cambon, Angelo Parini, Mustafa Lokhandwala.   

Abstract

BACKGROUND: Dopamine, via activation of D1-like and D2-like receptors, plays an important role in the regulation of renal sodium excretion. Recently, we demonstrated that dopamine D2-like receptor agonist (bromocriptine) stimulates p44/42 mitogen-activated protein kinases (MAPKs) and Na+,K(+)ATPase (NKA) activity in proximal tubular epithelial cells. Since both these parameters are compromised in ischemia/reperfusion (I/R) injury to the kidney, we investigated whether bromocriptine protects against the injury.
METHODS: In this study we used unilateral rat model of renal I/R injury. The Sprague-Dawley rats were divided into vehicle and bromocriptine groups. The vehicle and bromocriptine group was treated with vehicle and bromocriptine (500 microg/kg intravenously), respectively, 15 minutes before the induction of unilateral ischemia followed by 24- or 48-hour reperfusion. At the end of 24 or 48 hours the animals were sacrificed to collect control and ischemic kidney cortices, in which necrosis, apoptosis, NKA activity, NKA alpha1 subunit expression, and p44/42 MAPK phosphorylation were measured.
RESULTS: We found extensive necrosis, apoptosis, and decreased NKA activity (with no change in alpha1 subunit) in the ischemic kidney cortex compared to the nonischemic cortex from the vehicle-treated rats as early as 24 hours post-reperfusion. In contrast, I/R injury-induced necrotic, apoptotic, and decrease in NKA activity were absent in the outer cortex of bromocriptine-treated rats after 24 or 48 hours. Interestingly, we detected significantly higher phosphorylation of p44/42 MAPKs in control and ischemic kidneys of bromocriptine-treated rats compared to those of vehicle-treated rats.
CONCLUSION: Therefore, bromocriptine, a D1-like receptor agonist, may protect against I/R injury to proximal tubules of the kidney, via p44/42 MAPK activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15253716     DOI: 10.1111/j.1523-1755.2004.00783.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

1.  Intrarenal dopamine modulates progressive angiotensin II-mediated renal injury.

Authors:  Shilin Yang; Bing Yao; Yunfeng Zhou; Huiyong Yin; Ming-Zhi Zhang; Raymond C Harris
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-14

2.  The effect and mechanism of dopamine D1 receptors on the proliferation of osteosarcoma cells.

Authors:  Jun Gao; Chao Zhang; Feng Gao; Hongzhu Li
Journal:  Mol Cell Biochem       Date:  2017-02-08       Impact factor: 3.396

3.  Stimulation of Dopamine D3 Receptor Attenuates Renal Ischemia-Reperfusion Injury via Increased Linkage With Gα12.

Authors:  Zhen Wang; Weiwei Guan; Yu Han; Hongmei Ren; Xiaofeng Tang; Hui Zhang; Yukai Liu; Jinjuan Fu; Duofen He; Laureano D Asico; Pedro A Jose; Lin Zhou; Liyong Chen; Chunyu Zeng
Journal:  Transplantation       Date:  2015-11       Impact factor: 4.939

Review 4.  Renal Dopamine Receptors and Oxidative Stress: Role in Hypertension.

Authors:  Jian Yang; Van Anthony M Villar; Pedro A Jose; Chunyu Zeng
Journal:  Antioxid Redox Signal       Date:  2020-05-29       Impact factor: 8.401

5.  A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.

Authors:  Mark J Henderson; Kathleen A Trychta; Shyh-Ming Yang; Susanne Bäck; Adam Yasgar; Emily S Wires; Carina Danchik; Xiaokang Yan; Hideaki Yano; Lei Shi; Kuo-Jen Wu; Amy Q Wang; Dingyin Tao; Gergely Zahoránszky-Kőhalmi; Xin Hu; Xin Xu; David Maloney; Alexey V Zakharov; Ganesha Rai; Fumihiko Urano; Mikko Airavaara; Oksana Gavrilova; Ajit Jadhav; Yun Wang; Anton Simeonov; Brandon K Harvey
Journal:  Cell Rep       Date:  2021-04-27       Impact factor: 9.423

6.  Water Extract of Fructus Hordei Germinatus Shows Antihyperprolactinemia Activity via Dopamine D2 Receptor.

Authors:  Xiong Wang; Li Ma; En-Jing Zhang; Ji-Li Zou; Hao Guo; Si-Wei Peng; Jin-Hu Wu
Journal:  Evid Based Complement Alternat Med       Date:  2014-08-28       Impact factor: 2.629

7.  Therapeutic activity of sarpogrelate and dopamine D2 receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes.

Authors:  Mohammed Ahmed Fouad Shalaby; Hekma A Abd El Latif; Mohamed El Yamani; May Ahmed Galal; Sherifa Kamal; Ikhlas Sindi; Raneem Masaood
Journal:  BMC Pharmacol Toxicol       Date:  2021-10-26       Impact factor: 2.483

8.  Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats.

Authors:  Mohammed Fouad Shalaby; Hekma A Abd El Latif; Mohamed El Yamani; May Ahmed Galal; Sherifa Kamal; Ikhlas Sindi
Journal:  Curr Ther Res Clin Exp       Date:  2021-10-12

9.  Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects.

Authors:  Anthony H Cincotta; Eugenio Cersosimo; Mariam Alatrach; Michael Ezrokhi; Christina Agyin; John Adams; Robert Chilton; Curtis Triplitt; Bindu Chamarthi; Nicholas Cominos; Ralph A DeFronzo
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.